Europe • Frankfurt Stock Exchange • FRA:BSX • US1011371077
The current stock price of BSX.DE is 63 EUR. In the past month the price decreased by -23.54%. In the past year, price decreased by -37.62%.
ChartMill assigns a fundamental rating of 5 / 10 to BSX.DE. Both the profitability and the financial health of BSX.DE get a neutral evaluation. Nothing too spectacular is happening here.
Over the last trailing twelve months BSX.DE reported a non-GAAP Earnings per Share(EPS) of 2.56. The EPS increased by 21.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.42% | ||
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| Debt/Equity | 0.48 |
40 analysts have analysed BSX.DE and the average price target is 107.92 EUR. This implies a price increase of 71.3% is expected in the next year compared to the current price of 63.
For the next year, analysts expect an EPS growth of 14.83% and a revenue growth 11.42% for BSX.DE
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 2M6 | MEDTRONIC PLC | 16.59 | 110.612B | ||
| SHL | SIEMENS HEALTHINEERS AG | 17.07 | 46.09B | ||
| PHIA | KONINKLIJKE PHILIPS NV | 17.56 | 26.548B | ||
| PHI1 | KONINKLIJKE PHILIPS NV | 18.12 | 26.548B | ||
| BIM | BIOMERIEUX | 18.58 | 11.167B | ||
| DIA | DIASORIN SPA | 18.18 | 4.171B | ||
| OBCK | OTTOBOCK SE & CO KGAA | 18.36 | 3.759B | ||
| AFX | CARL ZEISS MEDITEC AG - BR | 11.84 | 2.522B | ||
| DRW3 | DRAEGERWERK AG - PREF | 11.93 | 1.665B | ||
| DRW8 | DRAEGERWERK AG | 9.59 | 1.328B |
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 53,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
BOSTON SCIENTIFIC CORP
300 Boston Scientific Way
Marlborough MASSACHUSETTS US
Employees: 53000
Phone: 13026365400
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 53,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
The current stock price of BSX.DE is 63 EUR. The price increased by 0.64% in the last trading session.
BSX.DE does not pay a dividend.
BSX.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
BOSTON SCIENTIFIC CORP (BSX.DE) currently has 53000 employees.